PREDICTIVE FACTORS FOR SUCCESSFUL BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS DOSE TAPERING IN RHEUMATOID ARTHRITIS

被引:0
|
作者
Loh, Min Yi [1 ]
Jones, Claire J. [1 ]
Peall, Adrian [1 ]
Trickey, Jeanette [1 ]
机构
[1] Wye Valley NHS Trust, Dept Rheumatol, Hereford, England
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
E075
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [2] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 787 - 794
  • [3] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [4] The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs
    Pombo-Suarez, Manuel
    Gomez-Reino, Juan
    PHARMACOLOGICAL RESEARCH, 2019, 148
  • [5] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [6] Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis
    Whittle, Samuel L.
    Glennon, Vanessa
    Johnston, Renea, V
    Avery, Jodie C.
    Bell, J. Simon
    Brennan, Sue E.
    Fong, Christopher
    Hissaria, Pravin
    Horgan, Ben
    O'Neill, Sean
    Pisaniello, Huai Leng
    Trevena, Lyndal
    Whittaker, Glen A.
    Wluka, Anita
    Buchbinder, Rachelle
    INTERNAL MEDICINE JOURNAL, 2022, 52 (10) : 1799 - 1805
  • [7] Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
    Tawaratsumida H.
    Setoguchi T.
    Arishima Y.
    Ohtsubo H.
    Akimoto M.
    Ishidou Y.
    Nagano S.
    Taketomi E.
    Sunahara N.
    Komiya S.
    BMC Research Notes, 10 (1)
  • [8] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [9] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [10] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163